2014 Fiscal Year Final Research Report
Study on the role of metalloprotease ADAM in insulin signaling
| Project/Area Number |
25860064
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pharmacology in pharmacy
|
|---|
| Research Institution | Hokkaido Pharmaceutical University School of Pharmacy |
|---|
Principal Investigator |
TAKAGURI Akira 北海道薬科大学, 薬学部, 准教授 (90623710)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | ADAM17 / Insulin signaling / Interluekin-1 / Endothelin-1 / Insulin resistance / Skeletal muscle cells |
|---|
| Outline of Final Research Achievements |
Insulin resistance on skeletal muscle cells contributes to the pathogenesis of type 2 diabetes. In this study, we examined the role of a disintegrin and metalloprotease ADAM17 on insulin signal transduction in L6 myotubes. Interluekin-1 increases ADAM17 expression through the ERK/NFκB and JNK/AP-1 signaling pathways. We also observed that endothelin-1 significantly inhibited insulin-induced IRS-1 tyrosine phosphorylation and Akt phosphorylation when ADAM17 were over-expressed. These results suggest that ADAM17 expression plays a pivotal role in ET-1-impaired insulin signal transduction in L6 myotubes.
|
| Free Research Field |
薬理学
|
